Crescent Biopharma, Inc. (CBIO) vs Contineum Therapeutics, Inc. (CTNM)
A side-by-side comparison of Crescent Biopharma, Inc. and Contineum Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$14.78HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
CTNM
Contineum Therapeutics, Inc.
$12.88HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — CBIO vs CTNM
growth of $100 · dividends reinvested · last 2yCBIO -95.3% (-78.3%/yr)CTNM -17.4% (-9.1%/yr)CTNM compounded faster over this window
Log scale — wide-divergence pair
CBIO CTNM
CBIO vs CTNM: by the numbers
- •CBIO is the larger company ($549M vs $485M market cap).
- •Both run net losses; CTNM's is the smaller (0.00% vs -1371.51% net margin).
Metrics side by side
Valuation
| Metric | CBIO | CTNM |
|---|---|---|
| P/S ratio | 46.20 | N/A |
| P/B ratio | 3.45 | 2.02 |
Profitability
| Metric | CBIO | CTNM |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1407.52% | 0.00% |
| Net margin | -1371.51% | 0.00% |
| ROE | -99.83% | -24.02% |
| ROIC | -102.59% | -27.22% |
Growth (annualized)
| Metric | CBIO | CTNM |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | N/A |
| Total return CAGR (5Y) | -24.40% | N/A |
Go deeper
Dig into the metrics
Crescent Biopharma ROEContineum Therapeutics ROECrescent Biopharma operating marginContineum Therapeutics operating marginCrescent Biopharma revenue growthContineum Therapeutics revenue growthCrescent Biopharma free cash flowContineum Therapeutics free cash flow
Crescent Biopharma & Contineum Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.